M. Timofeeva

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. Pasi, T. Lissitchkov, M. Ragni, 2021, Journal of thrombosis and haemostasis : JTH.

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

P. Collins, A. Tiede, M. Wolfsegger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

A. Sytkowski, G. Castaman, O. Stasyshyn, 2018, Journal of thrombosis and haemostasis : JTH.

The results of the use of Octofactor in patients with moderate and severe hemophilia A (data from a prospective, multicenter, open-label, observational study)

S. Morozov, E. Schiller, N. Zozulya, 2019, Russian Journal of Pediatric Hematology and Oncology.